Last reviewed · How we verify
Naropine
Naropine is a Small molecule drug developed by Rigshospitalet, Denmark. It is currently in Phase 1 development for Anesthesia for cesarean section, Local anesthesia, Major Nerve Block for Surgery. Also known as: Ropivacaine, TAP block, Wound infiltration, Placebo.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Naropine |
|---|---|
| Also known as | Ropivacaine, TAP block, Wound infiltration, Placebo |
| Sponsor | Rigshospitalet, Denmark |
| Target | Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 1 |
Approved indications
- Anesthesia for cesarean section
- Local anesthesia
- Major Nerve Block for Surgery
- Regional Anesthesia for Labor Pain
- Regional Anesthesia for Postoperative Pain
- Regional Anesthesia for Surgery
Common side effects
Key clinical trials
- Is PECS Block Equivalent to Paravertebral Block in Preventing Postoperative Pain After Breast Surgery? (PHASE4)
- Local Infiltration Analgesia vs Adductor Canal Block for Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE4)
- A Comparison of Postoperative Outcomes Provided by a Continuous Preperitoneal Infusion Versus Ultrasound Guided Rectus Sheath Block for Midline Emergency Laparotomy (NA)
- Adductor Canal Block: Continuous Infusion Versus Automatic Intermittent Bolus (NA)
- Perineural Dexmedetomidine for Ulnar Nerve Block. (PHASE2)
- Efficacy of Ultrasound-Guided Local Anesthetic Injection Into or Around the Sciatic Nerve for Lower Limb Anesthesia (NA)
- The Efficacy of Adductor-Canal-Blockade on Pain and Morphine Consumption After Revision Knee Arthroplasty (PHASE4)
- Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naropine CI brief — competitive landscape report
- Naropine updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI
Frequently asked questions about Naropine
What is Naropine?
What is Naropine used for?
Who makes Naropine?
Is Naropine also known as anything else?
What development phase is Naropine in?
What does Naropine target?
Related
- Target: All drugs targeting Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha
- Manufacturer: Rigshospitalet, Denmark — full pipeline
- Therapeutic area: All drugs in Pain
- Indication: Drugs for Anesthesia for cesarean section
- Indication: Drugs for Local anesthesia
- Indication: Drugs for Major Nerve Block for Surgery
- Also known as: Ropivacaine, TAP block, Wound infiltration, Placebo
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing